Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoricoxib vs Diclofenac CV Safety (MEDAL)
NCT00250445Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jan 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of etoricoxib in osteoarthritis (OA) and rheumatoid arthritis (RA) (2 arms), sponsored by Organon & Co. Primary endpoint: Incidence of Confirmed Thrombotic Cardiovascular Serious Adverse Experiences (Pooled). Started Jan 2003; status: completed.
02
Drugs
etoricoxib
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00250445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250445.